• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    H

    Hospital de Manises

    EST. 1998
    652论文总数
    8,774引用总数

    论文量&引用量时间轴

    机构学者

    论文(652)

    年份
    起
    –
    止
    排序
    1Minimal Disease Activity As a Therapeutic Goal in Atopic Dermatitis: Predictive Factors of Sustainability in a Multicenter Cohort
    Francisco Javier Melgosa Ramos, Santiago Guillén Climent, Marta Galarreta Pascual,Antonio Martorell, María Matellanes Palacios, Juncal Roca Ginés, Javier Sabater Abad, Eduardo Bernia Petit, Víctor González Delgado

    Minimal disease activity (MDA) is an emerging therapeutic goal in atopic dermatitis (AD), providing a multidimensional assessment of disease control. We conducted a retrospective multicenter study of adults with moderate-to-severe AD receiving biologics or JAK inhibitors. MDA was defined as Eczema Area and Severity Index (EASI) ≤ 3 and Pruritus Numerical Rating Scale (NRS) ≤ 1. Univariate analyses were performed to identify baseline predictors of sustained MDA at week 52 among patients who had previously achieved MDA at week 16. Among 197 patients with week 16 data, 107 (54.3

    2026Dermatology and Therapy(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Binimetinib and Cystoid Macular Edema: a Therapeutic Dilemma in Patients with Metastatic Melanoma.
    M Moro-Muniz, C Martinez Rubio, J Cañas Costa, D Martinez Tormo, A Avendaño Flores, D Salom

    We present the case of a woman with metastatic BRAF-mutated melanoma and a history of type 1 diabetes mellitus, who developed ocular toxicity secondary to Binimetinib treatment. She was initially treated with Vemurafenib and Cobimetinib, achieving complete remission. However, due to cumulative toxicities, therapy was switched to Encorafenib and Binimetinib in February 2023. After three months, she developed cystoid macular edema (CME), confirmed by optical coherence tomography (OCT). Management included Binimetinib dose reduction and topical ketorolac, resulting in initial improvement, although the CME recurred several months later. The rapid progression of metastatic melanoma in January 2024, with peritoneal carcinomatosis, massive ascites, and a left adrenal metastasis, limited further treatment options such as intravitreal anti-VEGF or dexamethasone. The patient ultimately began immunotherapy with Nivolumab and Ipilimumab, but died in February 2024 due to refractory abdominal septic shock. This case highlights the importance of early ophthalmologic monitoring and interdisciplinary collaboration in patients receiving MEK inhibitors.

    2026Archivos de la Sociedad Espanola de Oftalmologia(2026)
    引用
    AI阅读
    加入学术空间
    3Insulin Injection Behaviors and Association with Glycemic Outcomes in Patients with Diabetes: A Real-World Survey in Spain.
    Alba Galdón Sanz-Pastor,Alicia Justel Enríquez, Ana Sánchez Bao, Rosa P. Quílez Toboso, Beatriz González Aguilera,Mercedes Noval Font,Jessica Ares Blanco,Inés Modrego Pardo, Beatriz Voltas Arribas,Francisco Javier Ampudia-Blasco

    Optimal glycemic control is essential to prevent complications in diabetes, and insulin administration practices play a key role. This study assessed insulin injection behaviors and related glycemic outcomes among individuals using multiple daily injections in Spain. A cross-sectional online survey was conducted via an independent patient platform (Canal Diabetes). Adults (18–65 years) with type 1, type 2, or other forms of diabetes (e.g., maturity-onset diabetes of the young (MODY) or secondary diabetes) requiring daily insulin injections were included. Demographic, clinical, and behavioral data were analyzed using SPSS Statistics, version 23 (IBM Corp., Armonk, NY, USA). Among 288 participants (mean age: 43.7 ± 14.7 years; 28.8

    2026Diabetes Therapy(2026)
    引用
    AI阅读
    加入学术空间
    4Drusas Del Nervio Óptico Como Distractor Diagnóstico En Un Niño Con Síndrome De Alicia En El País De Las Maravillas
    M. Moro-Muniz, A. Rodríguez-Ballesteros,D. Salom Alonso

    Presentamos el caso de un varón de 10 años remitido por episodios visuales transitorios compatibles con síndrome de Alicia en el País de las Maravillas, descritos como sensación de alejamiento de los objetos. La exploración oftalmológica mostró una agudeza visual conservada y un segmento anterior normal, pero una papila izquierda sobreelevada, lo que obligó a descartar papiledema verdadero. La OCT macular fue normal, mientras que la OCT de papila evidenció asimetría estructural compatible con seudopapiledema. La resonancia magnética mostró dilatación aislada de las vainas de ambos nervios ópticos y discreta sobreelevación papilar izquierda, sin otros hallazgos sugestivos de hipertensión intracraneal. La ecografía orbitaria identificó un foco ecogénico sugestivo de drusas papilares. La evolución clínica y estructural estable apoyó el diagnóstico de seudopapiledema unilateral por drusas, probablemente independiente de los síntomas perceptivos.

    2026Archivos de la Sociedad Española de Oftalmología(2026)
    引用
    AI阅读
    加入学术空间
    5Real-world Use of Patiromer in Patients with Hyperkalaemia: A Retrospective Study from the Valencian Community.
    Francesc Moncho-Francés, Boris Gonzales-Candia,José Perez-Silvestre,Miriam Sandin,Pilar Sanchez-Perez,Rafael Garcia-Maset,Jonay Pantoja, Juan Antonio Carbonell-Asins, Elena Gimenez-Civera,Rafael De la Espriella,María Jesús Puchades,Julio Nuñez,

    BACKGROUND AND OBJECTIVE:Hyperkalaemia is common in patients with chronic kidney disease (CKD) treated with renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs). Although new potassium binders have demonstrated efficacy in clinical trials, evidence from real-world clinical practice remains limited. MATERIALS AND METHODS:We present a retrospective, observational, multicentre, non-interventional study aimed at evaluating the use of patiromer in patients with hyperkalaemia under routine clinical conditions in the Valencian Community. Patients who received patiromer for at least 3 months due to hyperkalaemia were included. The primary objective was to assess the evolution of serum potassium at 1, 3, 6, and 12 months after initiation of treatment. Secondary objectives included describing baseline patient characteristics, changes in RAASi and MRA therapy, and patiromer-related adverse events. RESULTS:A total of 59 patients were included. The baseline serum potassium level was 5.72 mmol/L, showing significant reductions at 1, 3, 6, and 12 months (5.02, 5.17, 5.11, and 5.01 mmol/L, respectively; all P < .001). Patiromer treatment enabled continuation of RAASi in 94.9% of patients and MRAs in 98.3%. The most frequent adverse events were gastrointestinal. Patiromer was discontinued in 8 patients (13.5%), with adverse effects accounting for half of these cases. CONCLUSIONS:Our study provides real-world evidence on the effectiveness, safety, and RAASi/MRA maintenance potential of patiromer in patients with CKD and hyperkalaemia under routine care. In this setting, patiromer proved effective and well tolerated for managing hyperkalaemia and preserving RAASi/MRA therapy.

    2026Nefrologia(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 652 篇论文

    合作机构(100)

    瓦伦西亚大学合作论文 85
    Hospital Universitari i Politècnic La Fe,Instituto de Investigación Sanitaria La Fe合作论文 62
    Hospital de Sant Pau合作论文 57
    Hospital General Universitario De Valencia合作论文 48
    Hospital Clínico Universitario de Valencia合作论文 43
    巴塞罗那医院合作论文 42
    Hospital Universitario Reina Sofía,Andalusian Health Service合作论文 41
    格雷戈里奥·马拉尼翁综合大学医院合作论文 39
    Hospital de Cruces合作论文 39
    Hospital Universitario La Paz合作论文 38

    机构统计